154 related articles for article (PubMed ID: 21531819)
41. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
[TBL] [Abstract][Full Text] [Related]
42. Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.
Morikawa T; Kuchiba A; Liao X; Imamura Y; Yamauchi M; Qian ZR; Nishihara R; Sato K; Meyerhardt JA; Fuchs CS; Ogino S
Int J Cancer; 2012 Sep; 131(5):1169-78. PubMed ID: 22038927
[TBL] [Abstract][Full Text] [Related]
43. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
[TBL] [Abstract][Full Text] [Related]
44. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors.
Lin JK; Lin PC; Lin CH; Jiang JK; Yang SH; Liang WY; Chen WS; Chang SC
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S680-6. PubMed ID: 24841357
[TBL] [Abstract][Full Text] [Related]
45. Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases.
Lang H; Baumgart J; Heinrich S; Tripke V; Passalaqua M; Maderer A; Galle PR; Roth W; Kloth M; Moehler M
Ann Surg; 2019 Nov; 270(5):799-805. PubMed ID: 31634180
[TBL] [Abstract][Full Text] [Related]
46. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
47. Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer.
Joung JG; Oh BY; Hong HK; Al-Khalidi H; Al-Alem F; Lee HO; Bae JS; Kim J; Cha HU; Alotaibi M; Cho YB; Hassanain M; Park WY; Lee WY
Clin Cancer Res; 2017 Dec; 23(23):7209-7216. PubMed ID: 28939741
[No Abstract] [Full Text] [Related]
48. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
49. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
Souglakos J; Philips J; Wang R; Marwah S; Silver M; Tzardi M; Silver J; Ogino S; Hooshmand S; Kwak E; Freed E; Meyerhardt JA; Saridaki Z; Georgoulias V; Finkelstein D; Fuchs CS; Kulke MH; Shivdasani RA
Br J Cancer; 2009 Aug; 101(3):465-72. PubMed ID: 19603024
[TBL] [Abstract][Full Text] [Related]
50. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
51. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.
Mao C; Wu XY; Yang ZY; Threapleton DE; Yuan JQ; Yu YY; Tang JL
Sci Rep; 2015 Feb; 5():8065. PubMed ID: 25639985
[TBL] [Abstract][Full Text] [Related]
52. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP
Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355
[TBL] [Abstract][Full Text] [Related]
53. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
[TBL] [Abstract][Full Text] [Related]
54. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
Nosho K; Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Zepf D; Yan L; Longtine JA; Fuchs CS; Ogino S
Neoplasia; 2008 Jun; 10(6):534-41. PubMed ID: 18516290
[TBL] [Abstract][Full Text] [Related]
55. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
Dienstmann R; Serpico D; Rodon J; Saura C; Macarulla T; Elez E; Alsina M; Capdevila J; Perez-Garcia J; Sánchez-Ollé G; Aura C; Prudkin L; Landolfi S; Hernández-Losa J; Vivancos A; Tabernero J
Mol Cancer Ther; 2012 Sep; 11(9):2062-71. PubMed ID: 22723336
[TBL] [Abstract][Full Text] [Related]
56. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
Katsios C; Ziogas DE; Roukos DH
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
[No Abstract] [Full Text] [Related]
57. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
[TBL] [Abstract][Full Text] [Related]
58. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
59. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.
Cejas P; López-Gómez M; Aguayo C; Madero R; de Castro Carpeño J; Belda-Iniesta C; Barriuso J; Moreno García V; Larrauri J; López R; Casado E; Gonzalez-Barón M; Feliu J
PLoS One; 2009 Dec; 4(12):e8199. PubMed ID: 20020061
[TBL] [Abstract][Full Text] [Related]
60. Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.
Kawaguchi Y; Lillemoe HA; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Kopetz S; Vauthey JN
J Am Coll Surg; 2019 Sep; 229(3):286-294.e1. PubMed ID: 31054911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]